Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

unimed del peru s.a. - furoato de mometasona; - suspension para inhalacion - por dosis1 dosis; furoato de mometasona 0.050000 g; - mometasona

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

unimed del peru s.a. - maleato de timolol; clorhidrato de dorzolamida; - solucion oftalmica - por dosis1 ml; maleato de timolol 6.830000 mg; clorhidrato de dorzolamida 22.260000 mg; - timolol, combinaciones

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

unimed del peru s.a. - ciprofloxacino; hidrocortisona; - solucion otica - por gramo1 ml; ciprofloxacino 3.000000 mg; hidrocortisona 10.000000 mg; - hidrocortisona y antiinfecciosos

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

unimed del peru s.a. - droguerÍa - meropenem trihidrato; - polvo para solucion inyectable - por vial 1.00 u - - meropenem

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

unimed del peru s.a. - olopatadina; - solucion oftalmica - por mililitro ; olopatadina 2.220000 mg; - olopatadina

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

farmindustria s.a. - droguerÍa - fosfato de clindamicina; - solucion inyectable - por mililitro 4.00 ml - - clindamicina

Unión Europea - español - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - el ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - agentes antineoplásicos - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 y 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

unimed del peru s.a. - solucion inyectable - por vial - Ácido zoledrónico

Venezuela - español - Instituto Nacional de Higiene

laboratorios vivax pharmaceuticals, c.a. - olopatadina - solucion - 0,2 %

Venezuela - español - Instituto Nacional de Higiene

laboratorios vivax pharmaceuticals, c.a. - ampicilina - sulbactam - polvo para solucion inyectable - 1 g - 0,5 g